Subklinik Hipertiroidizmde Beta-Bloker Tedavisinin Kan Basıncına Etkisi: Retrospektif Bir Gözlemsel Çalışma-Reference-Cited by-同舟云学术

Subklinik Hipertiroidizmde Beta-Bloker Tedavisinin Kan Basıncına Etkisi: Retrospektif Bir Gözlemsel Çalışma

Published:2023-09-26 Issue:3 Volume:12 Page:895-901
ISSN:2146-9954
Container-title:Gümüşhane Üniversitesi Sağlık Bilimleri Dergisi
language:
Short-container-title:

Author:

KAPLAN Aşkın Keskin¹^ORCID,SEZGİN Yılmaz²^ORCID

Affiliation:

1. MALTEPE ÜNİVERSİTESİ, TIP FAKÜLTESİ

2. Sağlık Bilimleri Üniversitesi

Abstract

This study aimed to investigate the effect of beta-blocker therapy on blood pressure in patients with subclinical hyperthyroidism and to elucidate the potential benefits of this treatment approach. This retrospective observational cohort study included 56 hypertensive patients with subclinical hyperthyroidism who received beta-blocker therapy. Patient data, including demographic characteristics, thyroid function tests, and blood pressure measurements, were collected from medical records and evaluated using statistical analysis with SPSS Statistics software. The cohort of hypertensive patients included 35 patients with uncontrolled blood pressure and 21 newly diagnosed patients, with a total average age of 55 and 73.2% of them being female. In newly diagnosed and uncontrolled hypertensive patients, TSH levels were below the average, and T3 levels were high (p

Funder

none

Publisher

Gumushane University

Subject

General Medicine

Reference29 articles.

1. 1. World Health Organization, International Society of Hypertension Writing Group. (2003). “World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension”. Journal of Hypertension, 21 (11), 1983-1992. https://doi.org/10.1097/01.hjh.0000084751.37215.d2

2. 2. Forouzanfar, M. H, Liu, P, Roth, G. A, Ng, M, Biryukov, S. and Marczak, L. (2017). “Global burden of hypertension and systolic blood pressure of at least 110 to 115 mm Hg, 1990-2015.” JAMA, 317 (2), 165-182. https://doi.org/10.1001/jama.2016.19043

3. 3. Mills, K. T, Bundy, J. D, Kelly, T. N, Reed, J. E, Kearney, P. M. and Reynolds, K. (2016). “Global disparities of hypertension prevalence and control: a systematic analysis of population-based studies from 90 countries”. Circulation, 134 (6), 441-450. https://doi.org/10.1161/CIRCULATIONAHA.115.018912

4. 4. Padwal, R, Straus, S. E. and McAlister, F. A. (2001). “Evidence based management of hypertension: cardiovascular risk factors and their effects on the decision to treat hypertension: evidence based review”. BMJ: British Medical Journal, 322 (7292), 977. https://doi.org/10.1136/bmj.322.7292.977

5. 5. Berta, E, Lengyel, I, Halmi, S, Zrínyi, M, Erdei, A, Harangi, M, Páll, D, Nagy, E. V, and Bodor, M. (2019). "Hypertension in thyroid disorders". Frontiers in Endocrinology, 10, 482. https://doi.org/10.3389/fendo.2019.00482.